# FDA Approves Datopotamab Deruxtecan (Datroway) for First-Line Triple-Negative Breast Cancer

> fda · REPORTED · 2026-05-01

The FDA approved datopotamab deruxtecan (Datroway), an antibody-drug conjugate co-developed by Daiichi Sankyo and AstraZeneca, for first-line treatment of immunotherapy-ineligible triple-negative breast cancer, representing a major new option for one of the hardest-to-treat breast cancer subtypes. The approval was one of five major oncology clearances by the FDA in Q2 2026.

About Daiichi Sankyo / AstraZeneca (Datroway): Datroway is an antibody-drug conjugate targeting Trop-2 developed by Daiichi Sankyo and AstraZeneca for treatment of various solid tumors including triple-negative breast cancer.

- Company: Daiichi Sankyo / AstraZeneca (Datroway)
- Sector: oncology
- Primary source: https://www.ajmc.com/compendium/breast-cancer

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.